Premium
Central nervous system EBV lymphoproliferative disorder in a patient with rhabdomyosarcoma
Author(s) -
Nakashima Kentaro,
Kodama Yuichi,
Nishikawa Takuro,
Nishimura Miho,
Ito Nobuhiro,
Fukano Reiji,
Nomura Yuko,
Ueba Tetsuya,
Inoue Tooru,
Oshima Koichi,
Okamura Jun,
Inagaki Jiro
Publication year - 2016
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12812
Subject(s) - medicine , rituximab , vincristine , rhabdomyosarcoma , cyclophosphamide , methotrexate , chemotherapy , lymphoproliferative disorders , central nervous system , lymphoma , epstein–barr virus , immunology , cancer research , virus , pathology , sarcoma
Epstein–Barr virus associated lymphoproliferative disorder (EBV‐LPD) occurs in patients with immunodeficiency, but it has not been well described in patients who have received chemotherapy for solid tumors. We describe a child with rhabdomyosarcoma who developed isolated central nervous system (CNS) EBV‐LPD during combination chemotherapy with vincristine, actinomycin D and cyclophosphamide. The patient was treated with high‐dose methotrexate (HD‐MTX) for CNS EBV‐LPD and then treated with rituximab in addition to HD‐MTX because of the emergence of LPD in the liver. I.v. rituximab combined with HD‐MTX might be effective therapy for CNS EBV‐LPD.